BBOT's BBO-11818 Shows Promising Anti-Tumor Activity in KRAS-Mutant Models
Event summary
- BBOT presented preclinical data at AACR 2026 showing BBO-11818's robust anti-tumor activity in KRAS-mutant models.
- BBO-11818 targets KRAS in both ON and OFF states, suppressing MAPK signaling and inhibiting cell proliferation.
- The drug demonstrated efficacy as monotherapy and in combination with other treatments across multiple cancer types.
- Updated Phase 1 clinical data for BBO-11818 expected in the second half of 2026.
The big picture
BBOT's presentation at AACR 2026 highlights the potential of BBO-11818 to address KRAS-mutant cancers, a significant unmet need in oncology. The drug's ability to target KRAS in both active and inactive states positions it as a differentiated therapy. The upcoming Phase 1 data will be critical in assessing its clinical viability and market potential.
What we're watching
- Clinical Progress
- The pace at which BBO-11818 advances through Phase 1 trials and demonstrates safety and efficacy in human patients.
- Combination Therapy
- How BBO-11818's combination with other treatments like BBO-10203, cetuximab, and anti-PD-1 will impact its therapeutic potential.
- Market Positioning
- Whether BBOT can establish BBO-11818 as a leading treatment for KRAS-mutant cancers, addressing significant unmet needs.
Related topics